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Available online xxxxBackground:Myelotoxic chemotherapy is associatedwith chemotherapy-induced (febrile) neutropenia (CIN/FN).
The MONITOR-GCSF study evaluated biosimilar ﬁlgrastim (Zarzio®) prophylaxis patterns, associated outcomes,
and determinants. We performed stratiﬁed analyses comparing elderly and non-elderly patients.
Methods: Comparative (elderly/non-elderly) analysis of demographics and clinical status, prophylaxis, associated
CIN/FN outcomes (CIN grade 4 [CIN4], FN, CIN/FN-related hospitalizations and chemodisturbances, composite),
and, per hierarchical modeling, determinants thereof evaluated at the patient- and cycle-level.
Results: There were no signiﬁcant differences between both cohorts in prophylaxis initiation/duration and
associated outcomes, but proportionately more elderly patients were correctly-prophylacted and fewer over-
prophylacted. Common determinants of poor CIN/FN outcomes included concomitant antibiotic prophylaxis,
impaired performance status, and any grade CIN in a previous cycle, whereas common determinants of good out-
comes included over-prophylaxis and prophylaxis initiation within 24–72 h. In the elderly, female gender, liver/
renal/cardiovascular disease, secondary prophylaxis, and under-prophylaxis were associated with poorer
outcomes. In the non-elderly, CIN4 at baseline or in a prior cycle was associated with poorer CIN/FN outcomes,
and higher biosimilar ﬁlgrastim dose and, perhaps counter-intuitively, under-prophylaxis with better outcomes.
Conclusion: Adequate GCSF support is essential for all patients, but especially for elderly patients with serious
chronic disease, certainly, if concomitant antibiotic prophylaxis is indicated and if a CIN4 episode occurred in a
prior cycle. The potential impact of impaired performance status, especially ECOG ≥ 2 at chemotherapy start or a
worsening to such during chemotherapy; under-prophylaxis, including inadequate secondary prophylaxis, should
be considered in elderly patients. Timely GCSF initiation and over-prophylaxis is associated with lower rates of
adverse CIN/FN events in elderly andnon-elderlypatients, and shouldbe further evaluated in prospective random-
ized trials.
© 2016 Published by Elsevier Ltd.Keywords:
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Guidelines [1–5] and reviews [e.g. [6–10], emphasize that elderly
patients with cancer are at markedly higher risk of chemotherapy-
induced (febrile) neutropenia (CIN; FN) than non-elderly patients.motherapy-induced (febrile)
iatr Oncol (2016), http://dx.dThis has signiﬁcant implications for clinical decision-making regarding
prophylaxis with granulocyte colony-stimulating factors (GCSF),
certainly for patients treated with myelotoxic chemotherapy regimens
with an FN risk between10% and20%.WhereasGCSF support is not gen-
erally indicated for regimens in this myelotoxicity range, it is strongly
recommended if patients are elderly.
There is limited real-world evidence about prophylaxis patterns,
outcomes, and determinants of these outcomes in elderly patientsneutropenia prophylaxis with biosimilar ﬁlgrastim in elderly versus
oi.org/10.1016/j.jgo.2016.09.006
2 M. Aapro et al. / Journal of Geriatric Oncology xxx (2016) xxx–xxxwith cancer – and whether and how these may differ from younger
patients with cancer. In the EuropeanMONITOR-GCSF study of 1447 pa-
tients with cancer receiving CIN/FN prophylaxis with biosimilar
ﬁlgrastim (EP2006, Zarzio®/Zarxio®, Hexal AG/ Sandoz International
GmbH) [11,12], we found that 17.4% of patients were under- and
26.0% were over-prophylacted relative to amended EORTC guidelines
[13]. We modeled the determinants of observed CIN/FN episodes and
CIN/FN-related hospitalizations and chemotherapy disturbances, both
at the patient-level (‘ever’ experienced during the period of chemother-
apy) and the cycle-level (during a given chemotherapy cycle). We
noticed an interaction between risk factors, including age ≥65, and
prophylaxis-intensity [14]. These analyses were not stratiﬁed by age,
only by the presence of risk factors.
The MONITOR-GCSF study included 598 patients (41.3%) age ≥65.
We report here on analyses comparing elderly versus non-elderly
patients in terms of prophylaxis patterns and ﬁve outcomes: CIN
grade 4 and FN episodes, CIN/FN-related hospitalizations and chemo-
therapy disturbances, and a composite reﬂecting the occurrence of
any of these outcomes.We also report on predictivemodeling for elder-
ly and non-elderly patients of determinants of these outcomes. In line
with our recent full-sample modeling [14], this included both static
models using patients and dynamic models using cycles as the unit of
analysis. The patient-levelmodels focus on outcomes ‘ever’ experienced
by a patient during the chemotherapy period and identify determinants
of CIN/FN risk to be assessed at the start of chemotherapy. The cycle-
level models center on outcomes during a particular chemotherapy
cycle and from one cycle to the next, evaluate determinants as patients
progress through their chemotherapy, and enable assessment of CIN/FN
risk at each cycle.2. Methods
The methodology of MONITOR-GCSF [11–14]. Methodology
elements relevant to this present analysis are summarized below.2.1. Design
MONITOR-GCSFwas a prospective real-world observational study of
patients with cancer receiving myelosuppressive chemotherapy whose
treating physicians prescribed CIN/FN prophylaxis with biosimilar
ﬁlgrastim, conducted in 140 centers in 12 European countries. Eligible
were adults (age ≥18) with stage 3 or 4 breast, ovarian, bladder,
or lung cancer; metastatic prostate cancer; stage 3 or 4 diffuse
large B-cell lymphoma or multiple myeloma. Patients were observed
for up to six cycles of chemotherapy.
We adopted the classical age 65 as cut-off as the MONITOR-GCSF
study was framed within the EORTC GCSF guidelines [4].2.2. Chemotherapy Regimens
Site investigators were asked to record the chemotherapy regimen
for each patient including agents, frequency, duration, and whether
the standard dose for the speciﬁed regimen was used. If the standard
dose was not used, investigators were requested to indicate the dosing.
These data were used to determine baseline FN risk.2.3. Outcomes
These included at both the patient- and cycle level: occurrence of a
CIN grade 4 (CIN4) or FN episode; CIN/FN-related hospitalization
or chemotherapy disturbance; and a composite index of any of these
outcomes occurring.Please cite this article as: Aapro M, et al, Chemotherapy-induced (febrile)
non-elderly cancer patients: Patterns..., J Geriatr Oncol (2016), http://dx.d2.4. Special Indices and Variables
Prophylaxis intensity classiﬁed patients as under-prophylacted,
correctly-prophylacted, or over-prophylacted relative to the amended
EORTC guidelines, as shown in Figs. 1 and 2.
The GCSF initiation score (GIS) (range 0–1) concerns the day of
biosimilar ﬁlgrastim initiation relative to the last day of chemotherapy
and the recommended timewindowof 24–72 h. AGIS of 1was assigned
in each cycle in which biosimilar ﬁlgrastim was started in this time
window, except that multiple myeloma patients could be started after
72 h. A score of 0 was given if initiated within 24 h after chemotherapy
(b24 h) or on day 10 or later. Partial credit of 0.75 and 0.50 was given if
initiated on days 4–6 or on days 7–9, respectively.
Knowledge about risk factorswas a 10-item questionnaire measuring
physicians' knowledge about FN risk factors (range 0–10).
Advanced disease was deﬁned as Stage 4 (Stage 3 if multiple
myeloma) disease and prior chemotherapy in the metastatic setting.
2.5. Variables Included in Modeling
Patient data at enrollment: age; gender; tumor type; history of CIN
grade 4 (CIN4), FN, repeated infections, and anemia; performance status
(ECOG); advanced disease; antibiotic prophylaxis; hemoglobin; liver,
cardiovascular, or renal disease; number of prior lines of chemotherapy;
radiotherapy; prophylaxis type, intensity, biosimilar ﬁlgrastim dose,
duration; GIS; and PRS. Since prophylaxis intensity was derived from
the guideline algorithm and based on chemotherapy-associated FN
risk categories (b10%, 10–20%, ≥20%), FN risk group was not included
as a predictor in the modeling.
Patient data at each cycle:hemoglobin; prophylactic antibiotic therapy;
ECOG;weight loss N5% in onemonth; CIN any grade (CIN1/4) in previous
cycle; infection in previous cycle; biosimilar ﬁlgrastim dose; biosimilar
ﬁlgrastim duration; PRS; and GIS.
Aggregate and ‘ever during study’ patient data: mean GIS; mean
biosimilar ﬁlgrastim duration; ‘ever’ ECOG ≥ 2; ‘ever’ CIN4; ‘ever’ FN;
‘ever’ CIN/FN-related hospitalization; ‘ever’ CIN/FN-related chemother-
apy disturbance; ‘ever’ positive CIN/FN composite score.
Center data: type (academic, academic-afﬁliated, non-academic);
case mix (cancer patients; newly diagnosed cancer patients;
chemotherapy-treated patients; chemotherapy-treated patients with
FN); FN prevention policy and/or protocol (sum with range 0–2);
number of guidelines used (EORTC, ESMO, ASCO, NCCN, and/or local;
sum, range 0–5).
Physician data: age; gender; attendance at educational event on FN
prevention in past year; knowledge about FN risk factors (range 0–10).
2.6. Specialized Statistical Issues
As cycle data were ‘nested’ under patients and patients under
centers, we used generalized estimating equations (GEE) to adjust for
this statistical dependence [15]. Chemotherapy disturbances were
estimated for the cycle after (lag = 1) the CIN/FN event occurred.
Logistic regression modeling was used to identify patient, center,
and physician variables predictive of the outcomes in both the
patient-level and cycle-level analyses. The direction and strength of
associations between predictors and outcomes was measured by
adjusted odds ratios (OR). The predictive performance of models was
tested by means of the c-statistic of concordance with bootstrapped
95%CIs.
3. Results
3.1. Patient Groups
There were 598 (41.3%) elderly and 849 (58.7%) non-elderly
evaluable patients. The non-elderly cohort had a signiﬁcantly higherneutropenia prophylaxis with biosimilar ﬁlgrastim in elderly versus
oi.org/10.1016/j.jgo.2016.09.006
Fig. 2. Treatment decision relative to amended EORTC guidelines in non-elderly patients.
Fig. 1. Treatment decision relative to amended EORTC guidelines in elderly patients.
3M. Aapro et al. / Journal of Geriatric Oncology xxx (2016) xxx–xxx
Please cite this article as: Aapro M, et al, Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar ﬁlgrastim in elderly versus
non-elderly cancer patients: Patterns..., J Geriatr Oncol (2016), http://dx.doi.org/10.1016/j.jgo.2016.09.006
Table 1
Patient demographics and clinical status; cancer and CIN/FN history and management.
Elderly 
598 (41.3%)
Non-elderly 
849 (58.7%) p
Demographics and clinical status
Gender
Male 49.8% 31.0%
Female 50.2% 69.0%
Age (M±SD,Mdn) 72.3 ± 5.2, 71 53.6 ± 8.5, 55
ECOG performance status 0 31.8% 47.3%
1 52.4% 45.2%
2 13.7% 5.6% <0.001
3 2.1% 1.8%
4 0.0% 0.1%
History of repeated infections 3.0% 2.3% n.s.
FN risk factors (EORTC) 
High risk
Age ≥ 65 years 100.0% 0.0%
Increased risk
0.022
Chemotherapy grading for risk of neutropenic fever
<10% 11.9% 9.8%
10–20% 52.5% 39.7%
≥20% 35.6% 50.5%
1Stage 4 (stage 3 if multiple myeloma) and prior chemotherapy in metastatic setting. 
Valid % used.
Shaded areas of the table indicate that no statistical comparisons were performed for these parameters.
n.s. non---significant
<0.001
Advanced disease1 14.7% 13.0% n.s.
History of FN 1.8% 2.2% n.s.
No antibiotic prophylaxis 88.4% 87.4% n.s.
Other factors
Poor performance and/or nutritional status 18.8% 9.6% <0.001
Female gender 50.2% 69.0% <0.001
Hemoglobin <12 g/dL 43.9% 37.4% 0.029
Renal, cardiovascular, or liver disease 31.9% 16.8% <0.001
Cancer
Tumor type
Solid 72.6% 80.5%
Hematological 27.4% 19.5%
Prior treatments
Chemotherapy 29.9% 33.1% n.s.
of these:
adjuvant 44.6% 49.6% n.s.
in metastatic setting 55.7% 47.2% n.s.
of these: prior lines of chemo
1 48.8% 53.9%
2 26.2% 27.8% n.s.
≥3 25.0% 18.3%
Radiation therapy 20.6% 17.8% n.s.
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Table 2
Zarzio® prophylaxis patterns.
Elderly Non-Elderly p
Type of prophylaxis
Primary 70.2% 73.7%
Secondary 29.8% 26.3% n.s.
Prophylaxis pattern
Under-prophylacted 25.8% 11.4%
Correctly-prophylacted 63.3% 51.9% b0.001
Over-prophylacted 10.9% 36.7%
Dose
30 MIU/day 62.4% 47.7%
48 MIU/day 37.6% 52.3% b0.001
Day of initiationa
0 15.0% 12.4%
1 26.5% 33.4%
2 13.8% 13.1%
3 7.5% 10.2%
4 3.2% 5.5%
5 7.2% 6.5%
6 9.8% 4.7%
7 7.9% 6.8%
8 4.5% 3.5%
9 1.2% 0.9%
10 0.9% 0.7%
11 0.6% 0.6%
≥12 1.9% 1.7%
By age group Mean SD Median
Non-elderly 2.95 2.91 2
Elderly 3.27 3.08 2 n.s.
Duration of prophylaxis (days) Elderly Non-elderly
1 3.0% 3.9%
2 5.3% 6.0%
3 11.6% 12.7%
4 7.9% 6.6%
5 44.6% 46.5%
6 7.8% 5.6%
7 11.4% 11.5%
8 3.0% 1.2%
9 0.9% 0.9%
10 1.9% 2.1%
11 0.2% 0.4%
12 0.3% 0.3%
13 b0.1% 0.2%
14 1.5% 1.9%
≥15 0.6% 0.2%
By age group Mean SD Median
Non-elderly 5.07 2.33 5
Elderly 5.18 2.30 5 n.s.
Duration Elderly Non-elderly
1–3 days 19.9% 22.6%
4–5 days 52.5% 53.1% n.s.
6+ days 27.6% 24.3%
n.s. non-signiﬁcant.
Cycle-level predictors are not applicable here.
a Zarzio® initiation expressed in days after chemotherapy (0 = same day; 1 = 1 day
after,2 = 2 days after, etc.).
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of overall sample); the elderly sample had signiﬁcantly higher ECOG
scores (p b 0.001) (Table 1). No signiﬁcant differences were observed
in rates of advanced disease, history of FN or antibiotic prophylaxis at
biosimilar ﬁlgrastim initiation (all p = n.s.). The elderly cohort had
higher baseline rates of the FN risk factors of hemoglobin b12 g/dl
(p= 0.029) and liver/renal/cardiovascular disease (p b 0.001); a higher
rate of hematological cancer (p = 0.022); however, rates of prior che-
motherapy and radiation did not differ (all p= n.s.). There was a signif-
icant trend for more regimens with 10–20% FN risk and fewer regimens
with ≥20% FN risk among elderly patients (p b 0.001). Of all evaluable
patients, 95.0% were prescribed the standard dose of the chemotherapy
regimen.
3.2. Prophylaxis Patterns
Similar proportions of patients in both cohorts received primary ver-
sus secondary prophylaxis, with similar patterns of day of initiation and
duration of prophylaxis (all p = n.s.). The elderly cohort includedmore
under-prophylacted and correctly-prophylacted patients, but fewer
over-prophylacted patients (Fig. 1) relative to the non-elderly (Fig. 2)
(p b 0.001). Almost two-thirds (62.4%) of elderly patients were treated
with a daily biosimilar ﬁlgrastim dose of 30 MIU, whereas among non-
elderly patients about half (47.7%) of patients were treated with 30
MIU/day and about half (52.3%) with 48 MIU/day (p b 0.001) (Table 2).
3.3. Clinical Outcomes
In both the patient-level (‘ever’ during study) and the cycle-level
(in a given cycle) analyses there were no statistically signiﬁcant dif-
ferences in the proportions of elderly and non-elderly patients
experiencing (febrile) neutropenia episodes, CIN/FN-related
hospitalizations or chemotherapy disturbances, or the composite
outcome (Table 3).
3.4. Predictive Risk Modeling: Elderly Cohort
3.4.1. Patient-Level Analysis
The risk of an elderly patient ‘ever’ experiencing a CIN4 episode
during the study increased if this patient was female, had liver, renal,
and/or cardiovascular disease, was prescribed concomitant antibiotic
prophylaxis at the initiation of biosimilar ﬁlgrastim prophylaxis, and
was administered the 48 MIU/day dose; but, perhaps counter-
intuitively, was mitigated if the patient had advanced cancer disease
(Tables 4 and 6). The only predictive factor of an elderly patient
experiencing an FN episode was receiving antibiotic prophylaxis.
An ECOG ≥ 2 anytime during the study was the only predictor of an
elderly patient being hospitalized for CIN/FN. Predictors of CIN/FN-
related disturbances among elderly patients included female gender
and being on secondary rather than primary prophylaxis. Elderly
patients were more likely to score positive on the composite score
if they were female; with liver, renal, and/or cardiovascular disease;
and on concomitant antibiotic prophylaxis; but was mitigated if
biosimilar ﬁlgrastim was initiated in the 24–72 h time window. The
c-statistics for these ﬁve models ranged from 0.58 to 0.69.
3.4.2. Cycle-Level Analysis
The likelihood of an elderly patient experiencing a CIN4 episode
during a given cycle increased if there was a CIN episode of any grade
(CIN1/4) in the previous cycle, with concomitant in-cycle antibiotic
prophylaxis, and if this patient was under-prophylacted; but was
mitigated if over-prophylacted (Tables 5 and 6). In-cycle FN risk for
elderly patients was higher if a CIN1/4 occurred in the preceding cycle
and the patient was receiving concomitant antibiotic prophylaxis
during the cycle. CIN1/4 in the previous cycle also increased the odds
of a CIN/FN-related hospitalization in the elderly, as did every additionalPlease cite this article as: Aapro M, et al, Chemotherapy-induced (febrile)
non-elderly cancer patients: Patterns..., J Geriatr Oncol (2016), http://dx.dpoint on ECOG. Elderly patients with a CIN episode of any grade in
a prior cycle were at much higher risk of a disruption to their chemo-
therapy in a later cycle, especially if they were being treated at an
academic-afﬁliated center with a high volume of chemotherapy-
treated patients; though mitigated if this was a high-volume cancer
center in general. A positive score on the composite outcome risk
for the present cycle was, again, a function of a CIN1/4 episode in the
preceding cycle and the patient receiving concomitant antibiotic
prophylaxis during the present cycle. The c-statistics ranged from 0.66
to 0.82.neutropenia prophylaxis with biosimilar ﬁlgrastim in elderly versus
oi.org/10.1016/j.jgo.2016.09.006
Table 3
Clinical outcomes at the patient and cycle levels.
Elderly Non-elderly p
Unit of analysis: patient
Neutropenia episodes
CIN grades 1 through 4 36.0% 34.0% n.s.
CIN grades 3 or 4 24.4% 21.9% n.s.
CIN grade 4 14.2% 12.5% n.s.
FN 5.9% 6.0% n.s.
CIN/FN-related hospitalizations 7.4% 5.2% n.s.
CIN/FN-related chemotherapy disturbancesa 10.5% 8.8% n.s.
CIN/FN-related composite outcomeb 23.8% 21.3% n.s.
Unit of analysis: cycle
Neutropenia episodes
CIN grades 1 through 4 15.0% 13.9% n.s.
CIN grades 3 or 4 8.7% 7.5% n.s.
CIN grade 4 4.1% 3.8% n.s.
FN 1.6% 1.3% n.s.
CIN/FN-related hospitalizations 1.9% 1.2% n.s.
CIN/FN-related chemotherapy disturbancesa 3.0% 2.5% n.s.
CIN/FN-related composite outcomeb 7.1% 6.5% n.s.
n.s. non-signiﬁcant.
a Chemotherapy disturbance includes dose reduction, discontinuation or delay. Measured
with 1-cycle lag.
b Includes any occurrence of CIN grade 4, FN, CIN/FN-related hospitalization, and/
or CIN/FIN-related chemotherapy disturbance.
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3.5.1. Patient-Level Analysis
No independent predictors of a non-elderly patient ‘ever’ experienc-
ing a CIN4 episode during the study were identiﬁed; however, several
were for an FN episode (Tables 4 and 6). The likelihood of an FN episode
anytime during the chemotherapy period increased in non-elderly pa-
tientswith ECOG ≥ 2 during the study and receiving concomitant antibi-
otic prophylaxis; but wasmitigated by being over-prophylacted, and by
increasing age. Non-elderly patients were at greater risk of being hospi-
talized over the course of chemotherapy treatment if during chemo-
therapy their performance status was ever ECOG ≥ 2 and if they were
under-prophylacted; yet this risk was lower if over-prophylacted.
Counter-intuitively, non-elderly patients with liver, renal, and/or car-
diovascular disease were less likely to have their next chemotherapy
cycle disrupted. A non-elderly patient's likelihood of a positive score
on the composite outcome increased if the patient presented with a
history of CIN4 at enrollment, but decreased if over-prophylacted. The
c-statistics ranged from 0.55 to 0.75.3.5.2. Cycle-Level Analysis
The risk of a non-elderly patient experiencing a CIN4 episode during
a given cycle rose in case of a CIN1/4 episode in the previous cycle, con-
comitant in-cycle antibiotic prophylaxis, patient history of CIN 4 at start
of chemotherapy, and being seen at an academic-afﬁliated center; but
was lessened with a GIS score of 1, being either under- or over-
prophylacted, and being treated at an academic cancer center
(Tables 5 and 6). In-cycle FN risk was higher for non-elderly patients
with a history of FN at enrollment, receiving concomitant antibiotic pro-
phylaxis during the cycle, and with each point increase in ECOG score;
but was mitigated by a 48 MIU/day dose, being under- or over-
prophylacted, and with increasing age. The likelihood of a CIN/FN-
related hospitalization during the present cycle was higher for non-
elderly patients with a history of CIN4 at enrollment, with each point
increase in ECOG, and in-cycle concomitant antibiotic prophylaxis; but
was lower, perhaps counter-intuitively, for patients receiving only
1–3 days of GCSF support in the cycle. Non-elderly patients' risk of a
disturbance to their next chemotherapy cycle rose if the patient experi-
enced a CIN1/4 episode in a previous cycle, had a history of CIN4 at the
start of the chemotherapy treatment, and was being seen at a cancerPlease cite this article as: Aapro M, et al, Chemotherapy-induced (febrile)
non-elderly cancer patients: Patterns..., J Geriatr Oncol (2016), http://dx.dcenter with a high volume of chemotherapy-treated patients. However,
the risk diminished as a function of the treating physician's score on the
knowledge about FN risk factors questionnaire. A non-elderly patient's
likelihood of a positive score on the composite outcome increased
with a history of CIN4 at enrollment, a CIN1/4 episode in a prior treat-
ment cycle, in-cycle antibiotic prophylaxis, higher ECOG score, and, per-
haps counter-intuitively, 4–5 days of biosimilar ﬁlgrastim prophylaxis
duration in the current cycle. This likelihoodwas offset by being treated
for a hematological malignancy; a GIS score of 1; perhaps counter-
intuitively, prophylaxis duration of 1–3 days in the cycle; and being
under- or over-prophylacted. The c-statistics ranged from 0.76 to 0.83.
4. Discussion
In this stratiﬁed analysis, no statistically signiﬁcant differences were
observed in the rates of CIN4 and FN episodes, CIN/FN-related hospital-
izations and chemotherapy disturbances, and a composite index of
these outcomes; at the patient-level (‘ever’ during the study) and at
the cycle-level (in a given cycle). This is a critical ﬁnding given that
elderly patients are considered to be at higher risk for CIN/FN. Further,
the elderly cohort tended to have poorer performance and/or
nutritional status, lower Hb levels, and more patients with liver/renal/
cardiovascular disease –which can be hypothesized to be compounding
risk factors for CIN/FN. The absence of differences in CIN/FN outcomes,
particularly in chemodisturbances and hospitalizations, underscores
that, despite higher risk proﬁles, clinicians managed elderly patients in
a remarkably effective manner – considering the likely increased rate
of CIN/FN and other complications in these patients.
This may be due, in part, to the fact that being elderly is a generally
accepted risk factor and clinicians will be concerned about CIN/FN,
and thus opt for a less myelotoxic chemotherapy regimen. Indeed,
about half of elderly patients were given chemotherapy with 10%–20%
FN risk and only about one-third regimens with ≥20% risk; whereas
the opposite was observed for non-elderly patients. Hence the absence
of differences in CIN/FN outcomes follows most likely from adequate
prophylaxis in combination with less aggressive chemotherapy.
Further, while there were no differences between the elderly and
non-elderly cohorts in terms of primary vs. secondary prophylaxis, or
day of initiation and duration of prophylaxis, two important differences
were noted. First, while biosimilar ﬁlgrastim dose (30 MIU/day vs. 40
MIU/day) was about equally distributed among non-elderly patients,
themajority (62.4%) of elderly patients received the lower dose. Second,
about two-thirds of elderly patients were correctly prophylacted, possi-
bly due to clinicians' awareness of elderly patients being at higher CIN/
FN risk. In addition, another 11% of elderly patients, all being treated
with regimens with b10% risk, received either primary prophylaxis or
secondary prophylaxis without evidence of CIN/FN in a prior cycle and
thus were over-prophylacted. Despite this clinical (over-)attention,
this left a quarter of elderly patients under-prophylacted, mainly
because of not receiving secondary prophylaxis when indicated.
The modeling results provide additional insights into CIN/FN pro-
phylaxis in elderly and non-elderly patients (Table 6). Across patient-
and cycle-level models, common predictors of poor patient outcomes
(CIN/FN, hospitalization and chemodisturbance, and/or composite)
included concomitant antibiotic prophylaxis, impaired performance
status, under-prophylaxis, and a CIN episode of any grade in a previous
cycle, whereas over-prophylaxis and initiation of prophylaxis in the
24–72 h time window were associated with better outcomes. Further,
elderly patients were at greater risk for poor outcomes if they were fe-
male, had liver/renal/cardiovascular disease, and were on secondary
prophylaxis – the latter being a proxy for a prior CIN/FN experience.
This conﬁrms our hypothesis above that the primary and major risk
factor of being elderly is compounded by general determinants in
common with non-elderly patients and by elderly-speciﬁc determi-
nants. In contrast, in non-elderly patients the single most important
determinants were a history of CIN4 at start of chemotherapy orneutropenia prophylaxis with biosimilar ﬁlgrastim in elderly versus
oi.org/10.1016/j.jgo.2016.09.006
Table 4
Modeling of predictors of outcomes using the patient as unit of analysis.
Outcomes
a. Elderly patients CIN grade 4 episode FN episode CIN/FN-related hospitalization CIN/FN-related chemotherapy disturbance Composite outcome
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Patient­level predictors
Female gender 1.811 (1.059–3.096) 0.030 2.023 (1.140–3.591) 0.016 1.819 (1.218–2.718) 0.004
Advanced disease 0.418 (0.190–0.919) 0.030
Liver/renal/cardiovascular disease 2.183 (1.255–3.799) 0.006 1.717 (1.076–2.740) 0.023
ECOG ≥2 during study 2.623 (1.371–5.019) 0.004
Concomitant antibiotic prophylaxisa 4.027 (2.025–8.009) b0.001 2.885 (1.248–6.669) 0.013 2.262 (1.271–4.028) 0.006
Secondary prophylaxis 2.247 (1.312–3.849) 0.003
Zarzio dose: higher dosea 2.018 (1.128–3.609) 0.018
GIS at enrolment (1 vs. 0) 0.573 (0.340–0.964) 0.036
Cycle-level predictors are not applicable here
b. Non-elderly patients CIN grade 4 episode FN episode CIN/FN-related hospitalization CIN/FN-related chemotherapy disturbance Composite outcome
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Patient-level predictors
Patient age (per 1 year) 0.972 (0.946–0.998) 0.038
Patient age (per 1 year) 0.972 (0.946–0.998) 0.038
Liver/renal/cardiovascular disease 0.370 (0.159–0.859) 0.021
History of CIN4 at enrolment 2.335 (1.215–4.488) 0.011
ECOG ≥2 during study 2.806 (1.636–4.812) b0.001 2.302 (1.166–4.548) 0.016
Concomitant antibiotic prophylaxisa 2.920 (1.583–5.386) 0.001
Over-prophylacted 0.190 (0.070–0.515) 0.001 0.314 (0.154–0.643) 0.002 0.362 (0.224–0.584) b0.001
Under-prophylacted 3.444 (1.423–8.335) 0.006
Center-level predictors
Physician age (per 1 year) 0.960 (0.925–0.996) 0.028
Cycle-level predictors are not applicable here
Cycle-level predictors are not applicable here.
a At enrolment/initiation cycle.
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Table 5
Modeling of predictors of outcomes using chemotherapy cycle as unit of analysis.
Outcomes
a. Elderly patients CIN grade 4 episode FN episode CIN/FN-related hospitalization CIN/FN-related chemotherapy
disturbance
Composite outcome
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Cycle-level predictors
ECOG score (per 1 point) 2.093 (1.509–2.902) b0.001
Concomitant antibiotic prophylaxis 3.741 (2.126–6.583) b0.001 3.017 (1.344–6.774) 0.008 2.603 (1.624–4.172) b0.001
CIN1/4 in previous cycle 3.648 (2.455–5.421) b0.001 3.285 (1.677–6.437) 0.001 4.049 (2.323–7.057) b0.001 11.540 (4.801–27.739) b0.001 3.961 (2.814–5.576) b0.001
Patient-level predictors
Under-prophylacted 4.282 (1.333–13.757) 0.015
Over-prophylacted 0.303 (0.100–0.918) 0.035
Center-level predictors
Cancer patients seen in 2009 (per 1 patient) 0.999 (0.998–1.000) 0.002
Chemotherapy-treated cancer patients in 2009
(per 1 patient)
1.001 (1.000–1.001) 0.001
Center type: academic-afﬁliated 4.919 (1.412–17.140) 0.012
b. Non-elderly patients CIN grade 4 episode FN episode CIN/FN-related hospitalization CIN/FN-related chemotherapy disturbance Composite outcome
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Cycle-level predictors
GIS 0.461 (0.268–0.794) 0.005 0.584 (0.384–0.889) 0.012
Zarzio dose: higher dose 0.467 (0.238–0.920) 0.028
Zarzio duration: 4–5 days 1.772 (1.221–2.570) 0.003
Zarzio duration: 1–3 days 0.193 (0.061–0.611) 0.005 0.459 (0.269–0.783) 0.004
ECOG score (per 1 point) 2.395 (1.748–3.281) b0.001 2.036 (1.386–2.991) b0.001 1.321 (1.037–1.683) 0.024
Concomitant antibiotic prophylaxis 6.211 (3.448–11.188) b0.001 5.667 (2.776–11.569) b0.001 5.591 (2.314–13.510) b0.001 4.855 (2.743–8.592) b0.001
CIN1/4 in previous cycle 4.692 (2.853–7.717) b0.001 9.542 (5.075–17.941) b0.001 3.800 (2.604–5.544) b0.001
Patient-level predictors
Patient age (per 1 year) 0.961 (0.935–0.989) 0.006
Hematological cancer 0.437 (0.252–0.756) 0.003
History of FN at enrollment 14.908 (6.452–34.448) b0.001
History of CIN Grade 4 at enrollment 2.318 (1.296–4.143) 0.005 4.020 (1.824–8.861) b0.001 2.902 (1.293–6.513) 0.010 2.370 (1.485–3.782) b0.001
Under-prophylacted 0.413 (0.191–0.895) 0.025 0.303 (0.104–0.885) 0.029 0.431 (0.234–0.795) 0.007
Over-prophylacted 0.481 (0.251–0.919) 0.027 0.254 (0.099–0.652) 0.004 0.535 (0.353–0.809) 0.003
Center-level predictors
Chemotherapy-treated cancer patients in 2009
(per 1 patient)
1.001 (1.000–1.001) 0.001
Knowledge of FN risk factors (0–10) (per 1 point) 0.790 (0.634–0.986) 0.037
Center type: academic 0.339 (0.181–0.637) 0.001
Center type: academic-afﬁliated 1.885 (1.118–3.179) 0.017
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Table 6
Comparative summary of risk-increasing (+) and risk-decreasing (−) determinants of outcomes.
a. Patient-level analysis CIN4 FN CIN/FN-related hospitalization CIN/FN-related chemodisturbance Composite outcome
Elderly Non-elderly Elderly Non-elderly Elderly Non-elderly Elderly Non-elderly Elderly Non-elderly
Patient age
Female gender
Liver/renal/cardiovascular disease
ECOG ≥ 2 during study 
Concomitant antibiotic prophylaxis
History of CIN4 at enrolment
Advanced disease
Secondary prophylaxis
GIS
Zarzio® dose: 48MIU/day
Under-prophylacted
Over-prophylacted
Physician age
b. Cycle-level analysis CIN 4 FN CIN/FN-related hospitalization CIN/FN-related chemodisturbance Composite outcome
Elderly Non-elderly Elderly Non-elderly Elderly Non-elderly Elderly Non-elderly Elderly Non-elderly
Patient age
ECOG score
Concomitant antibiotic prophylaxis
Hematological cancer
History of CIN4 at enrolment
History of FN at enrolment
CIN1/4 in previous cycle
GIS
Zarzio® dose: 48MIU/day
Zarzio® duration: 1-3 days
Zarzio® duration: 4-5 days
Under-prophylacted
Over-prophylacted
Academic center
Academic-affiliated center
Cancer patients seen in 2009
Chemotherapy-treated cancer patients in 2009
Knowledge of FN risk factors
Legend: Symbol Odds Ratio
1.001–1.999
2.000–3.999
4.000–5.999
6.000 or more
0.800–0.999
0.600–0.799
0.200–0.599
less than 0.200
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10 M. Aapro et al. / Journal of Geriatric Oncology xxx (2016) xxx–xxxexperiencing a CIN4 episode in a prior cycle. A biosimilarﬁlgrastim dose
of 48MIU/daywas associatedwith a lower likelihood of adverse CIN/FN
outcomes.
The models also yielded seemingly counter-intuitive ﬁndings. In el-
derly patients, higher biosimilar ﬁlgrastim dose (48 MIU/day), longer
duration (4–5 d vs. 1–3 d) of biosimilarﬁlgrastimprophylaxis, advanced
disease, and patient age were associated with better patient outcomes.
Likely, these variables are proxies for physician vigilance in terms of at-
tention to risk factors and pre-emptively prophylactingmore intensive-
ly. In non-elderly patients, under-prophylaxis may have had an
attenuating effect on CIN/FN; indicating perhaps those non-elderly
patients might be able to ‘withstand’ under-prophylaxis in a given
cycle – but not consistently throughout the entire period of chemother-
apy. The lower rate of neutropenic complications in non-elderly pa-
tients with 1–3 days of GCSF support may indicate a situation of over-
prophylaxis for a regimen or patient where this support was not
needed. Academic-afﬁliated cancer centers (but not academic cancer
centers) were associated with a higher probability of CIN4 episodes.
This is unlikely to be an indication of poor care, but rather of referral
patterns involving difﬁcult-to-treat and later-stage patients. The single
signal of physician knowledge of risk factors for CIN/FN being associated
with a lower probability of chemodisturbances is an encouraging
ﬁnding meriting further investigation.
In addition to limitations identiﬁed in our prior reports [13,14], the
present analyses warrant some caution. The age cut-off was 65 years
as cited in guidelines. Arguably, age 70 might be an appropriate cut-
off as well, as this age might be a composite marker that blends age,
frailty, and disease stage. Being a post hoc stratiﬁed analysis, no formal
geriatric assessment was performed and consequently the elderly
population is not well characterized in terms of geriatric parameters.
Possibly, only ‘better or ﬁtter’ elderly patients were referred to chemo-
therapy treatment and GCSF prophylaxis; hence the ﬁndings may only
apply to an elderly population of patients with cancer judged by oncol-
ogists to be eligible for chemotherapy treatment.
In routine clinical practice, concomitant antibiotic prophylaxis is ad-
ministered less frequently than GCSF support, and mainly in cases
where a relatively high risk for neutropenic infections is anticipated,
or such event has already occurred. Treatment outcomes in elderly
patients with hematological malignancies tend to be better than for
(metastatic) solid tumors, hence more elderly patients with hematologi-
cal disease may be referred for active treatment. The preponderance of
females in the non-elderly cohort is attributable to the proportion of
breast cancer. These variables suggest a selection bias in our study.
Our study provides important direction for prospective randomized
controlled studies. Especially the hypothesis that over-prophylaxis
combined with early initiation of GCSF support (within the recom-
mended 24–72 h time window) may compensate for factors associated
with poor prognosis, especially in elderly patients. Until such trial, the
reported association of over-prophylaxis with CIN/FN outcomes is
only an observation.
Clinically, our ﬁndings underscore the importance of assuring
adequate GCSF support, especially for elderly patients with established
serious chronic disease, certainly, if concomitant antibiotic prophylaxis
is indicated; and, at each cycle, if a CIN4 episode occurred in a prior
cycle. The impact of impaired performance status, especially ECOG ≥ 2,
under-prophylaxis, and inadequate secondary prophylaxis, should be
considered. Conversely, timely initiation of GCSF support and over-
prophylaxis may reduce the likelihood of adverse CIN/FN events in
elderly but also in non-elderly patients.
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